Exosome Analytics develops technologies and liquid biopsy tests for early cancer detection and prediction of treatment response. We profile onco- and histological markers on exosomes, what significantly increases the sensitivity and specificity of diagnostic tests and accelerates clinical integration.
Our first clinical product is an ovarian cancer diagnostic platform that is two times more sensitive in detection of early ovarian tumors than the current diagnostic approach. Starting with preclinical studies and subsequent large-scale clinical trials, we aim for EMA/FDA certification and commercialization of our platform within 1-2 years as an RUO product and later as a Class B in vitro diagnostic medical device. Our long-term vision extends beyond ovarian cancer to the development of a revolutionary exosome-based multi-cancer diagnostic platform. Early trials involving prostate and colon cancer patients have shown very promising results.